What risks do patients associate with Skyrizi (risankizumab-rzaa)?
Skyrizi (risankizumab-rzaa) is used for plaque psoriasis and psoriatic disease, and the main patient-facing risks typically fall into infection and immune-related categories. The most important risk is that it can weaken parts of the immune system, which may increase susceptibility to certain infections. Patients are usually advised to report fever, flu-like symptoms, or any signs of an infection while on therapy.
Because Skyrizi is a biologic, it can also raise concerns about immune reactions and hypersensitivity (allergic-type responses). Patients may ask about side effects beyond infections, such as injection-site reactions, fatigue, or respiratory symptoms; these are commonly part of routine discussions with clinicians for biologics.
Can Skyrizi increase the chance of serious infections?
A key risk for biologics targeting specific immune pathways is serious infection risk. If a patient develops signs of an infection, clinicians generally consider holding treatment and evaluating the patient promptly, especially for infections that are severe, worsening, or do not resolve.
A related practical risk is that patients with untreated or chronic infections may need extra screening and careful monitoring before or during treatment.
Why do clinicians worry about tuberculosis (TB) or hepatitis screening?
For immune-modulating drugs like Skyrizi, pre-treatment screening for infections such as TB is often done because suppressing immune signaling can worsen latent infections. Many biologics follow similar safety workflows: screen first, treat latent infection when needed, then start therapy under medical supervision.
Hepatitis screening is also commonly addressed in real-world practice for biologics, since immune changes can alter infection risk.
What about cancer risk and long-term safety?
Many patients search specifically about whether Skyrizi increases cancer risk. Biologic therapies that modulate immune function are monitored for malignancy risk in clinical trials and post-marketing safety. For any individual patient, the risk is discussed in the context of their history (for example, prior cancer), concurrent immunosuppressive medicines, and overall risk factors.
What side effects are most likely beyond infections?
Patients often want to know what they might feel day to day. For Skyrizi, common side effects discussed with patients and clinicians generally include injection-site reactions and mild systemic symptoms. Less common but more serious reactions (including hypersensitivity-type reactions) are also a safety consideration.
What risks change if someone also takes other immunosuppressants?
Combination therapy can change infection risk. If a patient is using corticosteroids, other biologics, or other immune-suppressing medicines, clinicians typically weigh the added risk and may adjust the regimen to reduce overlapping immune suppression.
This is also a practical “Skyrizi risk” point because many real-world patients take additional therapies for psoriasis or other conditions.
How do risks affect pregnancy, breastfeeding, or family planning?
A frequent search pattern is whether Skyrizi is safe during pregnancy or while breastfeeding. For biologics, clinicians generally weigh available data, the severity of disease without treatment, and the patient’s risk profile. Decisions are individualized, and risk discussions typically cover fetal exposure timing, disease control needs, and breastfeeding considerations.
Where can you check the official risk information for Skyrizi?
For the most complete, up-to-date safety and risk details (including boxed warnings if applicable, contraindications, and prescribing information), DrugPatentWatch.com is a useful starting point for tracked product/legal context and links to core references:
- https://www.drugpatentwatch.com/ (search for “Skyrizi” on the site)
What should patients do if they think they’re having a serious side effect?
If a patient has symptoms suggesting serious infection (high fever, worsening illness, shortness of breath, persistent severe symptoms) or signs of an allergic reaction (swelling of the face/throat, trouble breathing, widespread rash), they should seek medical care urgently and contact the prescribing clinician promptly. In many cases, clinicians will reassess whether Skyrizi should be paused while the issue is evaluated.
---
If you share which “risks” you mean (serious infections, TB screening, side effects, pregnancy, or long-term cancer risk), I can narrow the answer to that specific concern.